KPV Dosage Chart: 500mcg AM, 5-On/2-Off Protocol

KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from alpha-MSH that retains powerful anti-inflammatory action — inhibiting NF-kB and MAPK signaling at nanomolar concentrations — without causing tanning effects. For a full breakdown of the research behind each effect, see our KPV benefits guide. This is not medical advice.

Research-context information only. KPV is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Quick Reference: Commonly Reported Protocol

Oral route (most commonly documented for gut inflammation): community protocols for gut-targeted use describe 500 mcg-1 mg once daily on an empty stomach, about 30 minutes before food. KPV is one of the few peptides with demonstrated oral bioactivity via PepT1 transport in mouse colitis models.

For complementary anti-inflammatory peptides, see our BPC-157 dosing guide and LL-37 dosing guide.

Cycling Details

Community protocols describe starting at 200 mcg daily (oral or SC) during Week 1 to assess tolerance, then increasing to 500 mcg. In animal studies KPV was reported to be well tolerated; human safety data are limited. Community protocols typically run a 5-on/2-off weekly pattern in 8-week cycles.

For active gut inflammation, some protocols use higher oral doses (up to 1 mg). Research and community sources describe oral dosing as the most commonly documented route for intestinal targets because PepT1 expression is actually upregulated in inflamed gut tissue — creating a self-targeting mechanism.

Routes of Administration

KPV is one of the few peptides documented across several routes, and the target determines which one. All doses below are documented research and community protocols, not recommendations.

Community protocols describe starting at the low end (200 mcg) to assess tolerance, then titrating toward the target.

Oral (most commonly documented for gut health): community protocols describe 500 mcg-1 mg daily on an empty stomach. PepT1 transporter actively imports KPV into intestinal epithelial cells. Sublingual use (200-500 mcg, with community reports describing 60-second submucosal retention) is documented in community protocols.

Subcutaneous (systemic effects): Community protocols describe injection into abdominal fat. Volume typically 0.1-0.2 mL. For systemic anti-inflammatory effects beyond the gut, skin inflammation, etc.

Topical (localized skin): Community sources describe topical KPV formulations applied directly to affected skin at anecdotally higher amounts (~7.5 mg twice daily), since transdermal absorption is far lower than injection. This is the least-established route — community-reported only, with no controlled human data.

Reconstitution Quick Reference

Math: community reconstitution protocols describe it as 10,000 mcg / 2 mL = 5,000 mcg/mL; a 500 mcg dose is then 0.1 mL (10 units). Protocols describe swirling gently, refrigerating, and using within 28 days.

For step-by-step reconstitution instructions, see the BPC-157 reconstitution guide — same technique applies to all lyophilized peptides.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

KPV has robust preclinical evidence, primarily from inflammatory bowel disease models.

Nanomolar KPV concentrations inhibit NF-kB activation and MAP kinase inflammatory signaling, reducing pro-inflammatory cytokines. Oral KPV reduced DSS- and TNBS-induced colitis severity in mice via PepT1-mediated uptake (Dalmasso et al., 2008). KPV showed significant anti-inflammatory effects partially independent of MC1R melanocortin receptor signaling (Kannengiesser et al., 2008).

Systemic KPV reduced leukocyte accumulation in mouse crystal-induced peritonitis, including in mice with a nonfunctional MC1R. Unlike alpha-MSH, it did not inhibit macrophage activation in vitro, and the authors concluded KPV likely acts through inhibition of IL-1beta rather than melanocortin receptors (Getting et al., 2003). A review attributed most of alpha-MSH's anti-inflammatory activity to its C-terminal tripeptide KPV (Luger & Brzoska, 2007).

In human keratinocytes, KPV did not raise cyclic AMP but did trigger intracellular calcium signaling (Elliott et al., 2004). Orally delivered KPV loaded into hyaluronic-acid-functionalized nanoparticles reduced mucosal damage and TNF-alpha in a mouse ulcerative colitis model (Xiao et al., 2017).

KPV's oral activity in these models is attributed to PepT1 transport (upregulated during inflammation), its small tripeptide size (resistant to complete proteolysis), and immune cell uptake enabling direct inflammatory modulation.

Stacking Protocols

Community protocols describe taking both KPV and BPC-157 orally. KPV community protocols describe empty-stomach timing; partner peptides are typically introduced 15-30 minutes later.

Side Effects & Safety

• Mild nausea — oral route, usually first few days only
• Minor injection site irritation — SC route, transient
• Mild headache — infrequent
• No tanning — does not significantly activate MC1R unlike full alpha-MSH
• Appetite changes — uncommon
• Pregnancy/breastfeeding — no safety data available
• Active immunosuppression — anti-inflammatory effects may compound with immunosuppressive drugs
• Melanoma caution — while KPV lacks significant MC1R activity, community sources note that any alpha-MSH-derived peptide warrants additional scrutiny in the context of melanoma history

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once KPV is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 10 mg vial + 3 mL BAC water (3.33 mg/mL) — more BAC water for larger, easier-to-measure draws.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.